Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis

Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis

Abstract Background Uncontrolled T-cell activation plays a key role in systemic sclerosis (SSc). Arsenic trioxide (ATO) has immunological effects and has demonstrated potential in preclinical SSc models. In this study, we assessed the efficacy of ATO in Fra2 transgenic (Fra2TG) mice, which develop s...

Full description

Bibliographic Details
Main Authors: Anne Cauvet, Arthur Decellas, Christophe Guignabert, Dominique Rongvaux-Gaïda, Raphaël Thuillet, Mina Ottaviani, Ly Tu, François Rieger, Jérôme Avouac, Yannick Allanore
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Arthritis Research & Therapy
Subjects:
Systemic sclerosis
Arsenic trioxide
Pulmonary fibrosis
Pulmonary hypertension
Online Access:https://doi.org/10.1186/s13075-023-03143-2

Internet

https://doi.org/10.1186/s13075-023-03143-2

Similar Items